Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder

American Journal of Obstetrics and Gynecology

Volumn 201, Issue 2, 2009, Pages 139.e1-139.e8

  Segebladh, Birgitta ^a   Borgström, Anna ^a   Nyberg, Sigrid ^b   Bixo, Marie ^b   Sundström Poromaa, Inger ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

add back; clinical trial; estradiol; GnRH agonist; premenstrual dysphoric disorder; progesterone

Indexed keywords

ESTRADIOL; GESTAGEN; LEUPRORELIN; PLACEBO; PROGESTERONE;

ADD ON THERAPY; ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HEADACHE; HORMONE SUBSTITUTION; HUMAN; MIGRAINE; MONOTHERAPY; MOOD DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PHYSICAL DISEASE; POLYPHARMACY; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SLEEP DISORDER; SYMPTOM; TREATMENT OUTCOME;

EID: 67651111927     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.03.016     Document Type: Article

References (33)

1. Backstrom T., Andersson A., Andree L., et al. Pathogenesis in menstrual cycle-linked CNS disorders. Ann N Y Acad Sci 1007 (2003) 42-53
2. Sveindottir H., and Backstrom T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 79 (2000) 405-413
3. Mortola J.F., Girton L., and Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 72 (1991) 252A-F
4. Mezrow G., Shoupe D., Spicer D., Lobo R., Leung B., and Pike M. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 62 (1994) 932-937
5. Leather A.T., Studd J.W., Watson N.R., and Holland E.F. The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: a placebo-controlled study. Gynecol Endocrinol 13 (1999) 48-55
6. Sundstrom I., Nyberg S., Bixo M., Hammarback S., and Backström T. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 78 (1999) 891-899
7. Di Carlo C., Palomba S., Tommaselli G.A., Guida M., Di Spiezio Sardo A., and Nappi C. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 75 (2001) 380-384
8. Freeman E.W., Sondheimer S.J., Rickels K., and Albert J. Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study. J Clin Psychiatry 54 (1993) 192-195
9. Hammarback S., and Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 67 (1988) 159-166
10. Hammarback S., Ekholm U.B., and Backstrom T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol (Copenh) 125 (1991) 132-137
11. Brown C.S., Ling F.W., Andersen R.N., Farmer R.G., and Arheart K.L. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 84 (1994) 779-786
12. Wyatt K.M., Dimmock P.W., and O'Brien P.M. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev (2002) CD001396
13. Sundstrom I., Ashbrook D., and Backstrom T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 22 (1997) 25-38
14. Sundstrom I., Andersson A., Nyberg S., Ashbrook D., Purdy R.H., and Backstrom T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 67 (1998) 126-138
15. Epperson C.N., Haga K., Mason G.F., et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 59 (2002) 851-858
16. Bjorn I., Sundstrom-Poromaa I., Bixo M., Nyberg S., Backstrom G., and Backstrom T. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab 88 (2003) 2026-2030
17. Seippel L., and Backstrom T. Luteal-phase estradiol relates to symptom severity in patients with premenstrual syndrome. J Clin Endocrinol Metab 83 (1998) 1988-1992
18. Schmidt P.J., Nieman L.K., Danaceau M.A., Adams L.F., and Rubinow D.R. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 338 (1998) 209-216
19. Steiner M., Pearlstein T., Cohen L.S., et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt) 15 (2006) 57-69
20. Halbreich U., O'Brien P.M., Eriksson E., Backstrom T., Yonkers K.A., and Freeman E.W. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?. CNS Drugs 20 (2006) 523-547
21. Sundstrom-Poromaa I., Bixo M., Bjorn I., and Nordh O. Compliance to antidepressant drug therapy for treatment of premenstrual syndrome. J Psychosom Obstet Gynaecol 21 (2000) 205-211
22. Muse K.N., Cetel N.S., Futterman L.A., and Yen S.C. The premenstrual syndrome: effects of "medical ovariectomy". N Engl J Med 311 (1984) 1345-1349
23. Mitwally M.F., Gotlieb L., and Casper R.F. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause 9 (2002) 236-241
24. Sheehan D.V., Lecrubier Y., Sheehan K.H., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 suppl (1998) 22-57
25. De Lignieres B., Dennerstein L., and Backstrom T. Influence of route of administration on progesterone metabolism. Maturitas 21 (1995) 251-257
26. Erkkola R., Kumento U., Lehmuskoski S., Mattila L., and Mustonen M. No increased risk of endometrial hyperplasia with fixed long-cycle oestrogen-progestogen therapy after five years. J Br Menopause Soc 10 (2004) 9-13
27. Peeyananjarassri K., and Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 8 (2005) 13-23
28. Hammarback S., Damber J.E., and Backstrom T. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab 68 (1989) 125-130
29. Pearlstein T.B., Bachmann G.A., Zacur H.A., and Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72 (2005) 414-421
30. Yonkers K.A., Brown C., Pearlstein T.B., Foegh M., Sampson-Landers C., and Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106 (2005) 492-501
31. Freeman E.W., Kroll R., Rapkin A., et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 10 (2001) 561-569
32. Schmidt P.J., Nieman L.K., Grover G.N., Muller K.L., Merriam G.R., and Rubinow D.R. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N Engl J Med 324 (1991) 1174-1179
33. Eriksson O., Backstrom T., Stridsberg M., Hammarlund-Udenaes M., and Naessen T. Differential response to estrogen challenge test in women with and without premenstrual dysphoria. Psychoneuroendocrinology 31 (2006) 415-427